Is It Worth It,FDA's decision to remove tirzepatide from its drug shortage list

The question of are they going to stop making tirzepatide is a complex one, stemming from recent regulatory shifts and the resolution of a significant drug shortage. While the era of widespread compounded tirzepatide is coming to a close, the drug itself, in its approved forms, is not being discontinued. Instead, the focus has shifted to ensuring the availability of the legitimate, FDA-approved versions of tirzepatide and to regulate the production of its compounded counterparts.

For a considerable period, a tirzepatide injection shortage created significant challenges for patients relying on this medication for type 2 diabetes and weight management. This shortage led to a surge in the availability of compounded tirzepatide, often marketed as alternatives to brand-name drugs like Mounjaro and Zepbound. However, the landscape has been dramatically altered by recent FDA decisions.

The U.S. Food and Drug Administration (FDA) has formally announced the end of the tirzepatide shortage. This declaration, made with initial statements in October 2024 and further formalized in subsequent months, signifies that the manufacturer, Eli Lilly and Company, can now meet the growing demand for tirzepatide injections. This resolution has had a direct impact on the production and sale of compounded versions.

Following the resolution of the shortage, the FDA has issued directives requiring large-scale compounding facilities have to stop making tirzepatide. This includes ceasing the making of compounded versions of the drug. For smaller compounding pharmacies, the deadline to stop making tirzepatide was initially set for February 18, 2025, while larger outsourcing facilities had until March 19, 2025, to comply. The FDA's decision to remove tirzepatide from its drug shortage list has fundamentally altered the regulatory environment for these operations.

Despite these directives, some compounded tirzepatide remains available on certain online platforms, leading to confusion. Websites that were previously advertising tirzepatide are still offering it, even after the FDA ban. This has prompted further legal actions and stricter enforcement from regulatory bodies. Federal judges have begun intervening, with lawsuits aiming to halt the production and sale of these compounded copies. The FDA has also issued warnings to companies illegally selling unapproved drugs containing semaglutide, tirzepatide, or retatrutide, particularly those falsely labeled "for research."

The intention behind these regulatory changes is to ensure that patients have access to safe and effective medications. While compounded tirzepatide was initially seen as a solution during the shortage, concerns about its quality, purity, and efficacy have been raised. The FDA’s stance is that once a drug shortage is resolved, compounded versions are no longer permissible under the same regulatory framework. The FDA upheld this decision in December 2024, giving pharmacies deadlines to phase out compounded tirzepatide injections. Court rulings in May 2025 are also reinforcing this decision, confirming that sales of compounded tirzepatide have ended in March 2025.

The resolution of the tirzepatide shortage means that the drug is no longer being making in the same capacity by compounding pharmacies. The focus is now on the approved products, such as Mounjaro (for type 2 diabetes) and Zepbound (for obesity), both manufactured by Eli Lilly and Company. This shift aims to provide a more consistent and regulated supply chain for patients.

In summary, while the production of compounded tirzepatide is being phased out due to the resolution of the drug shortage and subsequent FDA regulations, tirzepatide itself, in its approved forms, is not being discontinued. The market is transitioning back to the officially recognized versions of the drug, ensuring greater oversight and patient safety. The supply of tirzepatide has eased, and the long-standing shortage has officially come to an end. Patients seeking tirzepatide should consult with their healthcare providers to discuss the approved treatment options available. The ability to make these medications under strict FDA guidelines is paramount for patient well-being.